Horizon Therapeutics Public Limited (NASDAQ:HZNP) EVP Andy Pasternak sold 23,250 shares of Horizon Therapeutics Public stock in a transaction dated Thursday, September 9th. The stock was sold at an average price of $107.84, for a total transaction of $2,507,280.00. Following the transaction, the executive vice president now directly owns 46,604 shares in the company, valued at $5,025,775.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
NASDAQ HZNP opened at $106.17 on Wednesday. The company has a quick ratio of 2.25, a current ratio of 2.55 and a debt-to-equity ratio of 0.63. Horizon Therapeutics Public Limited has a 52 week low of $66.41 and a 52 week high of $111.70. The stock has a market capitalization of $23.98 billion, a PE ratio of 47.19, a price-to-earnings-growth ratio of 1.56 and a beta of 1.08. The firm has a 50 day moving average of $103.16 and a two-hundred day moving average of $95.46.
Horizon Therapeutics Public (NASDAQ:HZNP) last issued its quarterly earnings data on Tuesday, August 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.75. The business had revenue of $832.55 million during the quarter, compared to the consensus estimate of $697.69 million. Horizon Therapeutics Public had a net margin of 20.27% and a return on equity of 27.41%. The company’s revenue was up 79.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.40 EPS. On average, equities research analysts expect that Horizon Therapeutics Public Limited will post 4.35 earnings per share for the current fiscal year.
A number of equities analysts have commented on HZNP shares. BMO Capital Markets lifted their target price on shares of Horizon Therapeutics Public from $118.00 to $132.00 and gave the stock an “outperform” rating in a research note on Thursday, August 5th. Zacks Investment Research upgraded shares of Horizon Therapeutics Public from a “sell” rating to a “hold” rating and set a $108.00 price target for the company in a research report on Thursday, July 29th. Maxim Group reiterated a “reduce” rating on shares of Horizon Therapeutics Public in a research report on Thursday, May 27th. The Goldman Sachs Group lifted their price target on shares of Horizon Therapeutics Public from $96.00 to $107.00 and gave the company a “neutral” rating in a research report on Tuesday, August 24th. Finally, Morgan Stanley lifted their price target on shares of Horizon Therapeutics Public from $103.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, August 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $117.73.
About Horizon Therapeutics Public
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.
See Also: QQQ ETF
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.